A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
==== Brooders ==== Brooding species are most often ahermatypic (not reef-building) in areas of high current or wave action. Brooders release only sperm, which is negatively buoyant, sinking onto the waiting egg carriers that harbor unfertilized eggs for weeks. Synchronous spawning events sometimes occur even with these species. After fertilization, the corals release planula that are ready to settle.
== Pharmacodynamics == Tiapride is a dopamine D2 and D3 receptor antagonist. It is more selective than other neuroleptic drugs such as haloperidol and risperidone, which not only target four of the five known dopamine receptor subtypes (D1-4), but also block serotonin (5-HT2A, 2C), α1- and α2-adrenergic, and histamine H1 receptors. Compared to these drugs, tiapride has a relatively moderate affinity for its target receptors, displacing 50 percent of 3H-raclopride binding at a concentration of 320 nM at D2 receptors and a concentration of 180 nM at D3 receptors. Tiapride displays a relatively high regional selectivity for limbic areas. One study found that, in contrast with haloperidol, which displays equal affinity for receptors in the rat limbic system and striatum, tiapride shows over three times as much affinity for limbic areas than striatal areas. Another study in rats found tiapride's affinity for the septum, a limbic region, to be over thirty times as high as for the striatum. Efficacy at the D2 receptor is moderate, with 80 percent of receptors occupied even in the presence of excess tiapride concentrations.
== Research == A major focus of his research is analytical separations theory and its application. His research group develops analytical techniques for molecular recognition and molecularly selective microextractions, and utilizes “green” separation procedures using aqueous solutions and nonvolatile polymeric systems. They have developed thin films for solid-phase micro extraction (SPME). Weber develops electrochemical detectors for use with liquid chromatography techniques. An important area of application is the identification of peptides, which help to control the body. Some of the systems which neuropeptides influence include pain, mood, social and emotional behavior, responses to stress, and memory. Understanding how peptides affect neurochemistry and other biological systems has important implications for medicine and pharmaceutical development. Dipeptides can be present in the brain at sub-picomole levels. To work effectively at this level, techniques must be highly sensitive and selective. Weber and his colleagues work on techniques to sample minute quantities from brain fluid and from single living cells. They are developing specialized sampling protocols with the goal of obtaining minute amounts of material from living organisms with minimal damage.
=== Hashimoto's thyroiditis === Hashimoto's thyroiditis is the most common thyroid disease and is characterized by abundant lymphocyte infiltrate and thyroid impairment. Recent research suggests a potential role for HHV-6 (possibly variant A) in the development or triggering of Hashimoto's thyroiditis.
Sources: en.wikipedia.org
"H" stands for "high metal" because CH chondrites may contain up to as much as 40% of metal. That makes them one of the most metal-rich of any of the chondrite groups, second only to the CB chondrites and some ungrouped chondrites such as NWA 12273. The first meteorite discovered was ALH 85085. Chemically, these chondrites are closely related to CR and CB groups. All specimens of this group belong only to petrologic types 2 or 3.
==== Advantage of argon ==== Making the plasma from argon, instead of other gases, has several advantages. First, argon is abundant (in the atmosphere, as a result of the radioactive decay of potassium) and therefore cheaper than other noble gases. Argon also has a higher first ionization potential than all other elements except He, F, and Ne. Because of this high ionization energy, the reaction (Ar+ + e− → Ar) is more energetically favorable than the reaction (M+ + e− → M). This ensures that the sample remains ionized (as M+) so that the mass spectrometer can detect it. Argon can be purchased for use with the ICP-MS in either a refrigerated liquid or a gas form. It should have a guaranteed purity of 99.9% Argon at a minimum. It is important to determine which type of argon will be best suited for the specific situation. Liquid argon is typically cheaper and can be stored in a greater quantity as opposed to the gas form, which is more expensive and takes up more tank space. If the instrument is in an environment where it gets infrequent use, then buying argon in the gas state will be most appropriate as it will be more than enough to suit smaller run times and gas in the cylinder will remain stable for longer periods of time, whereas liquid argon will suffer loss to the environment due to venting of the tank when stored over extended time frames. However, if the ICP-MS is to be used routinely and is on and running for eight or more hours each day for several days a week, then going with liquid argon will be the most suitable.
== Background == In 1994, with record labels trying to capitalize on the popularity of grunge and alternative rock bands like Nirvana, Pearl Jam, and Soundgarden, Local H caught the attention of Polydor Records, which was then in the process of merging with Island Records. Island released the band's debut studio album, Ham Fisted, the following year, but it sold below expectations and Island pressured the band's A&R rep, Joe Bosso, to drop them. Instead, Bosso pushed them into quickly recording a follow-up before Island could cancel their contract. Ahead of the release of As Good as Dead, frontman Scott Lucas was informed by Island that the album needed to sell at least 100,000 copies for the band to remain with the label.
== Risk factors == There is limited research on LADA and its etiology. As with both T1D and T2D, the risk of developing LADA depends on both genetic and environmental factors. Genetic risk factors for LADA are similar to T1D, e.g. it is affected by the HLA complex, but also genetic variants associated with T2D have been identified in LADA. LADA has several lifestyle risk factors in common with T2D, such as obesity, physical inactivity, smoking and consumption of sweetened beverages, all of which are linked to insulin resistance. Obesity has been shown to increase the risk of LADA in several studies, and one study showed that the risk was particularly high in combination with having diabetes in the family. Less physical activity increases the risk of developing LADA. A Swedish study showed that low birth weight, in addition to increasing the risk of T2D, increases the risk of LADA. Although smoking has been shown to increase the risk of T2D and coffee consumption to decrease it, the results regarding these products and LADA are unclear. However, results from two studies based on the same population seem to indicate that coffee consumption increases the risk of LADA. Sweetened beverages and processed red meat have been shown to increase the risk of LADA, while consumption of fatty fish has been shown to have a protective effect.
Cellular adhesion and development. The adhesion between cells is a characteristic of multicellular organisms that enables tissue specialization and therefore increases cell complexity. Adhesion of cell epithelia involves the actin cytoskeleton in each of the joined cells as well as cadherins acting as extracellular elements with the connection between the two mediated by catenins. Interfering in actin dynamics has repercussions for an organism's development, in fact actin is such a crucial element that systems of redundant genes are available. For example, if the α-actinin or gelation factor gene has been removed in Dictyostelium individuals do not show an anomalous phenotype possibly due to the fact that each of the proteins can perform the function of the other. However, the development of double mutations that lack both gene types is affected. Gene expression modulation. Actin's state of polymerization affects the pattern of gene expression. In 1997, it was discovered that cytocalasin D-mediated depolymerization in Schwann cells causes a specific pattern of expression for the genes involved in the myelinization of this type of nerve cell. F-actin has been shown to modify the transcriptome in some of the life stages of unicellular organisms, such as the fungus Candida albicans. In addition, proteins that are similar to actin play a regulatory role during spermatogenesis in mice and, in yeasts, actin-like proteins are thought to play a role in the regulation of gene expression.
Sources: en.wikipedia.org
Minoxidil was discovered in 1963 and was introduced for treatment of high blood pressure in 1971. In 1971, researchers unexpectedly discovered that minoxidil causes hair growth, resulting in it being repurposed for treatment of hair loss and approved in topical form for this use in 1988. Topical minoxidil became available over-the-counter in 1996. Low-dose oral minoxidil (LDOM) emerged for treatment of hair loss in 2015 and dramatically increased in popularity starting in 2022. Extended-release oral minoxidil and sublingual minoxidil were developed in the 2020s for hair loss and are in late-stage trials. Aside from its use in humans, minoxidil is extremely toxic to cats and dogs even in small amounts.
The two substrates of this enzyme are L-serine and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are L-3-oxo-alanine, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-serine:NADP+ 3-oxidoreductase.
The Australian Rugby League Commission Limited (ARL), formerly the Australian Rugby Football League Limited is an Australian rugby league football competition operator. It was founded in 1986 as the Australian Rugby Football League Limited and succeeded the Australian Rugby Football League Board of Control which had been formed in 1924. Since its inception, the ARL has administered the Australian national team and represented Australia in international rugby league matters. Prior to 1998, the code in Australia had been principally administered by individual state leagues on a domestic basis, and the ARL on a national and international basis.
== Upholstery filling == Buckwheat hulls are used as filling for a variety of upholstered goods, including pillows. The hulls are durable and do not insulate or reflect heat as much as synthetic filling. They are sometimes marketed as an alternative natural filling to feathers for those allergic to feathers. However, medical studies to measure the health effects of pillows manufactured with unprocessed and uncleaned hulls concluded that such pillows contain higher levels of a potential allergen that may trigger asthma in susceptible individuals than do synthetic-filled pillows.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.